BioSpace News Archive

Xenon Pharmaceuticals Inc. announced that the company will present at the BofA Securities Health Care Conference 2024 taking place May 14-16, 2024 in Las Vegas, NV.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced financial results for the first quarter of 2024 and associated Company developments.

Surrozen, Inc., a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, provided first quarter 2024 financial results and business updates.

NeuroPace, Inc., a medical device company focused on transforming the lives of people living with epilepsy, reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Cytek® Biosciences, Inc., a leading cell analysis solutions company, reported financial results for the first quarter ended March 31, 2024.

Apollomics Inc., a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced that it entered into subscription agreements for a private investment in public equity financing that is expected to result in gross proceeds of approximately $6 million to the Company, before deducting offering expenses.

Bionano Genomics, Inc. reported financial results for the first quarter ended March 31, 2024.

Standard BioTools Inc. announced financial results for the first quarter ended March 31, 2024 and recent business updates.

Seer, Inc. announced the launch of the Seer Technology Access Center in Bonn, Germany, providing the European biopharma and life sciences communities with service programs and the latest mass spectrometry technologies to optimize deep, unbiased proteomic studies.

Cytokinetics, Incorporated reported financial results for the first quarter of 2024. Net loss for the first quarter was $135.6 million, or $1.33 per share, compared to net loss for the first quarter of 2023 of $131.3 million, or $1.38 per share.